ABIVAX Societe Anonyme (NASDAQ:ABVX) was last year’s top performer, skyrocketing by 1,742.28 percent in 2025 due to upbeat analyst outlooks, strong clinical trial results, and its inclusion in Nasdaq’s biotechnology index. ABVX also earned “buy” recommendations from Guggenheim Securities, Truist Financial, and Citizens, with price targets of $175, $140, and $131, respectively.

ABIVAX Societe Anonyme (NASDAQ:ABVX) officially joined the Nasdaq biotechnology index (NBI) on December 22, reflecting the company’s progress in advancing obefazimod through successful Phase 3 ABTECT Induction trials for ulcerative colitis. Patients who took 50 mg of obefazimod saw significant improvement, suggesting real disease healing. ABVX remains a potential investment with promising AI stocks holding greater returns.

Read more at Yahoo Finance: How Abivax (ABVX) Turned Heads With Whopping 1700% Surge in 2025